Published in J Obes on January 29, 2013
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). Biochim Biophys Acta (2014) 0.95
Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol (2015) 0.95
Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne) (2014) 0.88
Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. World J Gastroenterol (2014) 0.87
Could the improvement of obesity-related co-morbidities depend on modified gut hormones secretion? World J Gastroenterol (2014) 0.85
Non-alcoholic fatty liver disease and liver transplantation: outcomes and advances. World J Gastroenterol (2013) 0.84
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther (2015) 0.84
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol (2016) 0.81
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci (2016) 0.81
Prevalence of non-alcoholic fatty liver disease in four different weight related patient groups: association with small bowel length and risk factors. BMC Res Notes (2015) 0.79
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.79
Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. Obes Surg (2016) 0.78
Global publication trends and research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic review. Springerplus (2015) 0.77
Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med (2014) 0.77
Essential amino acid ingestion as an efficient nutritional strategy for the preservation of muscle mass following gastric bypass surgery. Nutrition (2015) 0.75
The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. Obes Surg (2016) 0.75
Changes in adiposity and other cardiometabolic risk factors following Roux-en-Y gastric bypass: A 12-month prospective cohort study in Chinese patients. Indian J Gastroenterol (2017) 0.75
Simultaneous living donor liver transplant with sleeve gastrectomy for metabolic syndrome and NASH-related ESLD-First report from India. Indian J Gastroenterol (2017) 0.75
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med (2004) 17.91
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med (2009) 13.91
Long-term mortality after gastric bypass surgery. N Engl J Med (2007) 10.75
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg (1995) 9.02
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia (2003) 5.91
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med (2006) 5.54
AGA technical review on nonalcoholic fatty liver disease. Gastroenterology (2002) 4.61
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Epidemiology of non-alcoholic fatty liver disease. Dig Dis (2010) 3.44
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology (2003) 3.23
Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg (2001) 2.96
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology (2004) 2.77
Risks and benefits of bariatric surgery: current evidence. Cleve Clin J Med (2006) 2.31
Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol (2005) 2.21
The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18
Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol (2009) 2.09
Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci (1995) 2.06
Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab (2008) 2.03
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology (2008) 2.02
Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis (2007) 2.01
Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci (1997) 1.99
The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg (2004) 1.83
Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci (2005) 1.80
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord (1998) 1.76
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70
Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology (2009) 1.67
Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (2006) 1.65
Treatment of non-alcoholic fatty liver disease. Postgrad Med J (2006) 1.63
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) (2008) 1.59
Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) (2009) 1.52
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery (2004) 1.51
Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol (1991) 1.45
Relationship between the preoperative body mass index and the resolution of metabolic syndrome following Roux-en-Y gastric bypass. Metab Syndr Relat Disord (2012) 1.43
Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol (2007) 1.39
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Bariatric surgery. Dtsch Arztebl Int (2011) 1.23
Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab (2008) 1.21
Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg (2006) 1.21
Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg (2002) 1.19
The effect of gastric bypass surgery on hypertension in morbidly obese patients. Arch Intern Med (1994) 1.17
Effects of obesity surgery on the metabolic syndrome. Arch Surg (2004) 1.15
The liver in obesity. AMA Arch Intern Med (1952) 1.14
How big a problem is non-alcoholic fatty liver disease? BMJ (2011) 1.13
Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol (2006) 1.13
Liver disease in patients with diabetes mellitus. J Clin Gastroenterol (2006) 1.13
Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg (2006) 1.12
Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.11
Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol (1995) 1.10
Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res (2005) 1.08
The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis (2012) 1.08
Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2003) 1.07
Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc (2008) 1.06
Nonalcoholic fatty liver disease treated by gastroplasty. Dig Dis Sci (2006) 1.03
Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg (2012) 1.02
Metabolic syndrome: yet another co-morbidity gastric bypass helps cure. Surg Obes Relat Dis (2006) 0.98
Laparoscopic sleeve gastrectomy: an innovative new tool in the battle against the obesity epidemic in Canada. Can J Surg (2010) 0.98
Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg (2007) 0.97
Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg (2005) 0.97
Resolution of diabetes mellitus and metabolic syndrome following Roux-en-Y gastric bypass and a variant of biliopancreatic diversion in patients with morbid obesity. Obes Surg (2007) 0.95
Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2009) 0.95
Biliary pancreatic diversion and laparoscopic adjustable gastric banding in morbid obesity: their long-term effects on metabolic syndrome and on cardiovascular parameters. Cardiovasc Diabetol (2009) 0.94
Effect of bariatric surgery on liver fibrosis. Obes Surg (2012) 0.92
Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf) (2007) 0.92
CRP reduction following gastric bypass surgery is most pronounced in insulin-sensitive subjects. Int J Obes (Lond) (2005) 0.89
Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis (2010) 0.89
Metabolic syndrome after laparoscopic bariatric surgery. Obes Surg (2008) 0.89
Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg (2006) 0.88
Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg (2005) 0.87
Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. J Gastrointest Surg (2000) 0.87
Bariatric surgical outcomes. Surg Clin North Am (2005) 0.87
Are bariatric surgical outcomes worth their cost? A systematic review. J Am Coll Surg (2005) 0.87
Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications (2007) 0.86
Roux-en-Y gastric bypass versus a variant of biliopancreatic diversion in a non-superobese population: prospective comparison of the efficacy and the incidence of metabolic deficiencies. Obes Surg (2006) 0.86
Histological findings in the liver before and after gastric bypass. Obes Surg (2006) 0.85
Long-term results of bariatric restrictive procedures: a prospective study. Obes Surg (2010) 0.84
Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci (2007) 0.83
Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery. Exp Clin Endocrinol Diabetes (2012) 0.82
Effects of weight loss induced by bariatric surgery on the prevalence of metabolic syndrome. Arq Bras Cardiol (2009) 0.82
Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly (2002) 0.82
Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg (2005) 0.80
Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion (1990) 0.79
Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discov Today (2010) 0.77
[Effect of gastric bypass on the metabolic syndrome and on cardiovascular risk]. Nutr Hosp (2010) 0.76
Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) (2009) 1.52
The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J Obes (2012) 0.86
Emergency colectomy for fulminant Clostridium difficile colitis: Striking the right balance. Scand J Gastroenterol (2011) 0.85
Venous gangrene and cancer: a cool look at a burning issue. Int Semin Surg Oncol (2007) 0.84
Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf (2007) 0.83
Hemoglobinopathies in the Sudan. Hemoglobin (2008) 0.81
Metabolic syndrome and ischemic mitral regurgitation: other piece of the jigsaw. Asian Cardiovasc Thorac Ann (2006) 0.81
Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect? Expert Opin Drug Saf (2015) 0.81
Obesity-related glomerulopathy: another nail in the coffin of the epidemic of end-stage renal disease. J Clin Pathol (2007) 0.80
Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab J Gastroenterol (2012) 0.80
Moderate ischemic mitral regurgitation (IMR) and metabolic syndrome: where are we now and where are we going? Cardiovasc Diabetol (2006) 0.79
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (2005) 6(1):131-139. Expert Opin Drug Saf (2006) 0.77
Potential Benefit of Metformin as Treatment for Colon Cancer: the Evidence so Far. Asian Pac J Cancer Prev (2015) 0.77
Frequency and patterns of abnormal Pap smears in Sudanese women with infertility: What are the perspectives? J Cytol (2013) 0.77
Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol (2010) 0.76
Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. World J Gastroenterol (2010) 0.75
Fatal fat embolism complicating cemented total knee replacement: another manifestation of the metabolic syndrome? Arch Orthop Trauma Surg (2006) 0.75
Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy? Expert Opin Emerg Drugs (2006) 0.75
Abnormal glucose tolerance and non-esterified fatty acids (NEFAs) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH. J Clin Gastroenterol (2007) 0.75
Insulin resistance and nitric oxide and associated renal injury: innocent bystanders or accessories to the crime? N Z Med J (2006) 0.75
Cardiovascular disease: is C-reactive protein the bad guy? Diabetes Res Clin Pract (2006) 0.75
Statins and breast cancer: a smoking gun or guilt by association? Expert Opin Drug Saf (2006) 0.75
Urinary cytopathologic findings in renal allograft recipients in Sudan: trends, outcome and challenges. Saudi J Kidney Dis Transpl (2014) 0.75
Ezetimibe and recent clinical trials: a look on the bright side. Expert Opin Drug Saf (2010) 0.75
Heart failure as a consequence of ischemic mitral regurgitation (IMR): the hidden threat of the metabolic syndrome. Med Hypotheses (2006) 0.75
Insulin resistance, the renin-angiotensin system, and associated renal injury: is insulin resistance the culprit? Ren Fail (2007) 0.75